Total Payments
$469,559
2024 Payments
$9,056
Companies
29
Transactions
388
Medicare Patients
5,103
Medicare Billing
$1.3M
Payment Breakdown by Category
Consulting$220,190 (46.9%)
Other$154,943 (33.0%)
Research$54,306 (11.6%)
Travel$32,763 (7.0%)
Food & Beverage$7,268 (1.5%)
Education$89.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $220,190 | 74 | 46.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $148,836 | 63 | 31.7% |
| Unspecified | $54,306 | 34 | 11.6% |
| Travel and Lodging | $32,763 | 71 | 7.0% |
| Food and Beverage | $7,268 | 139 | 1.5% |
| Honoraria | $4,040 | 3 | 0.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,067 | 3 | 0.4% |
| Education | $89.00 | 1 | 0.0% |
Payments by Type
General
$415,253
354 transactions
Research
$54,306
23 transactions
Ownership
$0
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $170,769 | 97 | $0 (2022) |
| Celgene Corporation | $111,152 | 87 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $50,563 | 28 | $0 (2021) |
| Millennium Pharmaceuticals, Inc. | $46,529 | 21 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $25,649 | 40 | $0 (2024) |
| GlaxoSmithKline, LLC. | $13,050 | 7 | $0 (2022) |
| Janssen Global Services, LLC | $8,470 | 8 | $0 (2020) |
| Janssen Biotech, Inc. | $7,480 | 20 | $0 (2024) |
| Celularity Inc. | $6,085 | 4 | $0 (2020) |
| Janssen Scientific Affairs, LLC | $5,681 | 5 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,056 | 27 | F. Hoffmann-La Roche AG ($3,095) |
| 2023 | $22,875 | 19 | Celgene Corporation ($15,012) |
| 2022 | $19,530 | 28 | E.R. Squibb & Sons, L.L.C. ($12,685) |
| 2021 | $28,305 | 20 | Amgen Inc. ($15,024) |
| 2020 | $44,391 | 28 | Amgen Inc. ($20,303) |
| 2019 | $75,633 | 67 | Celgene Corporation ($24,526) |
| 2018 | $118,064 | 89 | Amgen Inc. ($45,556) |
| 2017 | $151,706 | 110 | Amgen Inc. ($73,835) |
All Payment Transactions
388 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,150.00 | General |
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $741.00 | General |
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $141.81 | General |
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $36.37 | General |
| 12/08/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $60.00 | General |
| 12/06/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $103.34 | General |
| Category: Oncology | ||||||
| 10/31/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Consulting Fee | Cash or cash equivalent | $2,180.00 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $148.84 | General |
| Category: Oncology | ||||||
| 10/05/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $23.46 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $110.40 | Research |
| Study: PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | ||||||
| 10/01/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $69.00 | Research |
| Study: PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | ||||||
| 09/27/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $56.96 | General |
| 09/24/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $36.62 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $9.42 | General |
| Category: Oncology | ||||||
| 08/12/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), CARVYKTI, TECVAYLI | Food and Beverage | In-kind items and services | $119.19 | General |
| Category: Oncology | ||||||
| 06/13/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $3,040.00 | General |
| 06/13/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $54.63 | General |
| 06/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $494.00 | General |
| 06/03/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $145.99 | General |
| Category: Oncology | ||||||
| 05/31/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $67.95 | General |
| Category: ONCOLOGY | ||||||
| 04/08/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $16.35 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 04/03/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $68.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| P3 Kd v KdD in Relapsed-Refractory MM (CANDOR) | Amgen Inc. | $12,109 | 1 |
| CC-4047-MM-014 - Immune profiling of relapsed or refractory multiple myeloma patients treated with pomalidomide and low-dose dexamethasone in combination with daratumumab | Celgene Corporation | $5,914 | 1 |
| CC-4047-MM-014 | Celgene Corporation | $4,881 | 1 |
| Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Amgen Inc. | $4,506 | 1 |
| Targeting MCL-1 in Hematologic Malignancies: Rationale and Progress | Amgen Inc. | $3,767 | 1 |
| A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patient | Amgen Inc. | $3,449 | 1 |
| Immune profiling of relapsed or refractory multiple myeloma patients treated with pomalidomide and low-dose dexamethasone in combination with daratumumab (CC-4047-MM-014) | Celgene Corporation | $3,392 | 1 |
| CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma (CRB-401) | Celgene Corporation | $2,866 | 1 |
| P3 Kd v KdD in Relapsed/Refractory MM (CANDOR) | Amgen Inc. | $2,799 | 2 |
| CC-4047-MM-005 | Celgene Corporation | $2,533 | 1 |
| 4220 - CFZ Ph3 H2H vs Velcade (2011-003) ENDEAVOR | Amgen Inc. | $2,217 | 1 |
| CRB-401 - CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma | Celgene Corporation | $1,326 | 1 |
| A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma (CC-220-MM-001) | Celgene Corporation | $1,144 | 1 |
| Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref | Amgen Inc. | $1,074 | 1 |
| Health related quality of life (HRQoL) outcomes from the phase III CANDOR study comparing carfilzomib | Amgen Inc. | $688.29 | 1 |
| Efficacy and safety of weekly carfilzomib (70 mg/m 2), dexamethasone, and daratumumab (KdD70) is co | Amgen Inc. | $462.77 | 1 |
| CC-4047-MM-007 - Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma | Celgene Corporation | $442.00 | 1 |
| Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with | Amgen Inc. | $205.66 | 1 |
| PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | Regeneron Pharmaceuticals, Inc. | $179.40 | 2 |
| Resultados actualizados de los etudios de carfilzomib aspire y endeavor | Amgen Inc. | $175.65 | 1 |
| Efficacy and Safety of Carfilzomib, Dexamethasone, and Daratumumab (KdD) Twice-Weekly at 56 mg/m2 an | Amgen Inc. | $175.14 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 897 | 5,604 | $990,642 | $325,934 |
| 2022 | 15 | 1,458 | 6,260 | $846,641 | $315,958 |
| 2021 | 12 | 1,371 | 3,920 | $522,695 | $289,005 |
| 2020 | 12 | 1,377 | 4,885 | $783,037 | $393,857 |
Total Patients
5,103
Total Services
20,669
Medicare Billing
$1.3M
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 393 | 1,401 | $421,207 | $208,366 | 49.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 296 | 495 | $118,000 | $50,525 | 42.8% |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 2023 | 19 | 312 | $270,912 | $33,294 | 12.3% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 32 | 3,120 | $121,740 | $18,272 | 15.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 35 | 35 | $15,990 | $6,713 | 42.0% |
| 38221 | Biopsy of bone marrow | Office | 2023 | 19 | 19 | $11,768 | $2,771 | 23.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 12 | 68 | $3,894 | $1,879 | 48.2% |
| 85097 | Bone marrow, smear interpretation | Office | 2023 | 21 | 25 | $8,075 | $1,460 | 18.1% |
| 38220 | Aspiration of bone marrow sample for diagnosis | Office | 2023 | 19 | 19 | $10,884 | $1,345 | 12.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 51 | 110 | $8,172 | $1,310 | 16.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 397 | 1,128 | $338,400 | $169,940 | 50.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 308 | 528 | $132,000 | $53,461 | 40.5% |
| Q5111 | Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg | Office | 2022 | 21 | 288 | $206,496 | $39,425 | 19.1% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2022 | 24 | 2,080 | $41,600 | $13,127 | 31.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 410 | 1,148 | $34,440 | $8,531 | 24.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 36 | 36 | $17,640 | $6,332 | 35.9% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 14 | 36 | $5,760 | $5,742 | 99.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 41 | 160 | $8,000 | $4,490 | 56.1% |
| 38221 | Biopsy of bone marrow | Office | 2022 | 26 | 26 | $13,650 | $3,790 | 27.8% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2022 | 11 | 600 | $13,800 | $3,406 | 24.7% |
| 85097 | Bone marrow, smear interpretation | Office | 2022 | 36 | 43 | $11,825 | $2,572 | 21.8% |
| 38220 | Aspiration of bone marrow sample for diagnosis | Office | 2022 | 26 | 26 | $12,350 | $1,833 | 14.8% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2022 | 11 | 11 | $4,400 | $1,816 | 41.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 49 | 89 | $4,450 | $1,101 | 24.7% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2022 | 48 | 61 | $1,830 | $389.80 | 21.3% |
About Dr. David Siegel, MD
Dr. David Siegel, MD is a Hematology healthcare provider based in Hackensack, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457310815.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Siegel, MD has received a total of $469,559 in payments from pharmaceutical and medical device companies, with $9,056 received in 2024. These payments were reported across 388 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($220,190).
As a Medicare-enrolled provider, Siegel has provided services to 5,103 Medicare beneficiaries, totaling 20,669 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Hackensack, NJ
- Active Since 03/22/2006
- Last Updated 01/26/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1457310815
Products in Payments
- Kyprolis (Biological) $123,311
- NINLARO (Drug) $84,675
- Pomalyst (Drug) $39,767
- Kyprolis (Drug) $29,910
- Revlimid (Drug) $21,212
- BLENREP (Biological) $11,650
- BB-2121 (Drug) $7,356
- DARZALEX (Biological) $6,410
- EMPLICITI (Biological) $5,435
- Vectibix (Biological) $5,000
- CARVYKTI (Drug) $4,251
- Imbruvica (Drug) $3,547
- SARCLISA (Biological) $2,909
- XPOVIO (Drug) $2,577
- KEYTRUDA (Biological) $2,055
- VENCLEXTA (Biological) $2,045
- Blincyto (Biological) $1,650
- BOSULIF (Drug) $1,516
- CC-220 (Drug) $1,144
- IMBRUVICA (Drug) $556.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Hackensack
Dr. James Mccloskey, M.d, M.D
Hematology — Payments: $2.8M
Hematology $2.8M
Dr. Jamie Koprivnikar, M.d, M.D
Hematology — Payments: $1.5M
Hematology $1.5M
Dr. Andrew Pecora, Md, MD
Hematology — Payments: $1.4M
Hematology $1.4M
Dr. David Vesole, Md, MD
Hematology — Payments: $1.1M
Hematology $1.1M
Dr. Lori Leslie, M.d, M.D
Hematology — Payments: $669,511
Hematology $669,511
Dr. Robert Alter, Md, MD
Hematology — Payments: $539,884
Hematology $539,884